Diarylureas as Antitumor Agents
The diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently repor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/11/1/374 |
| id |
doaj-3d30eb4f57d84326acb7fd2093cdb065 |
|---|---|
| record_format |
Article |
| spelling |
doaj-3d30eb4f57d84326acb7fd2093cdb0652021-01-03T00:00:40ZengMDPI AGApplied Sciences2076-34172021-01-011137437410.3390/app11010374Diarylureas as Antitumor AgentsAlessia Catalano0Domenico Iacopetta1Maria Stefania Sinicropi2Carlo Franchini3Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70126 Bari, ItalyDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, ItalyDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, ItalyDepartment of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70126 Bari, ItalyThe diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently reported in literature. The first to come into the market as an anticancer agent was sorafenib, followed by some others. In this review, we survey progress over the past 10 years in the development of new diarylureas as anticancer agents.https://www.mdpi.com/2076-3417/11/1/374diarylureasantitumor agentsbis-aryl ureashepatocellular carcinoma (HCC)renal cell carcinoma (RCC)gastrointestinal stromal tumors (GISTs) |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Alessia Catalano Domenico Iacopetta Maria Stefania Sinicropi Carlo Franchini |
| spellingShingle |
Alessia Catalano Domenico Iacopetta Maria Stefania Sinicropi Carlo Franchini Diarylureas as Antitumor Agents Applied Sciences diarylureas antitumor agents bis-aryl ureas hepatocellular carcinoma (HCC) renal cell carcinoma (RCC) gastrointestinal stromal tumors (GISTs) |
| author_facet |
Alessia Catalano Domenico Iacopetta Maria Stefania Sinicropi Carlo Franchini |
| author_sort |
Alessia Catalano |
| title |
Diarylureas as Antitumor Agents |
| title_short |
Diarylureas as Antitumor Agents |
| title_full |
Diarylureas as Antitumor Agents |
| title_fullStr |
Diarylureas as Antitumor Agents |
| title_full_unstemmed |
Diarylureas as Antitumor Agents |
| title_sort |
diarylureas as antitumor agents |
| publisher |
MDPI AG |
| series |
Applied Sciences |
| issn |
2076-3417 |
| publishDate |
2021-01-01 |
| description |
The diarylurea is a scaffold of great importance in medicinal chemistry as it is present in numerous heterocyclic compounds with antithrombotic, antimalarial, antibacterial, and anti-inflammatory properties. Some diarylureas, serine-threonine kinase or tyrosine kinase inhibitors, were recently reported in literature. The first to come into the market as an anticancer agent was sorafenib, followed by some others. In this review, we survey progress over the past 10 years in the development of new diarylureas as anticancer agents. |
| topic |
diarylureas antitumor agents bis-aryl ureas hepatocellular carcinoma (HCC) renal cell carcinoma (RCC) gastrointestinal stromal tumors (GISTs) |
| url |
https://www.mdpi.com/2076-3417/11/1/374 |
| work_keys_str_mv |
AT alessiacatalano diarylureasasantitumoragents AT domenicoiacopetta diarylureasasantitumoragents AT mariastefaniasinicropi diarylureasasantitumoragents AT carlofranchini diarylureasasantitumoragents |
| _version_ |
1724351216388931584 |